Cargando…

HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation

Triple-negative breast cancer (TNBC) is a highly malignant type of breast cancer and lacks effective therapy. Targeting cysteine-dependence is an emerging strategy to treat the mesenchymal TNBC. However, many TNBC cells are non-mesenchymal and unresponsive to cysteine deprivation. To overcome such r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alothaim, Tahiyat, Charbonneau, Morgan, Tang, Xiaohu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8155140/ https://www.ncbi.nlm.nih.gov/pubmed/34040090 http://dx.doi.org/10.1038/s41598-021-90527-6

Ejemplares similares

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
por: Maccallini, Cristina, et al.
Publicado: (2022)

LIFR inhibition enhances the therapeutic efficacy of HDAC inhibitors in triple negative breast cancer
por: Li, Mengxing, et al.
Publicado: (2021)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

Improving Insulin Sensitivity With HDAC Inhibitor
por: Ye, Jianping
Publicado: (2013)

Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer
por: Dowling, Catríona M., et al.
Publicado: (2021)

Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
por: Bhattacharya, Udayan, et al.
Publicado: (2023)

Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo
por: Jeon, Hyein, et al.
Publicado: (2016)

CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer
por: Han, Xin-le, et al.
Publicado: (2021)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
por: Rodríguez, María Del Carmen Rodríguez, et al.
Publicado: (2022)

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours
por: Toosi, Behzad M., et al.
Publicado: (2018)

HDAC6 Deacetylase Activity Is Required for Hypoxia-Induced Invadopodia Formation and Cell Invasion
por: Arsenault, Dominique, et al.
Publicado: (2013)

Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation
por: Pai, Jih-Tung, et al.
Publicado: (2022)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors
por: Bobrowicz, Malgorzata, et al.
Publicado: (2020)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor
por: Dong, Sheng, et al.
Publicado: (2017)

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
por: Cosenza, Maria, et al.
Publicado: (2018)

E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
por: Decourtye-Espiard, Lyvianne, et al.
Publicado: (2021)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
por: Kwilas, Anna R., et al.
Publicado: (2016)

Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer
por: Guerra, Fabiana Sélos, et al.
Publicado: (2021)

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
por: Tang, Lin, et al.
Publicado: (2020)

HDAC6 regulates dental mesenchymal stem cells and osteoclast differentiation
por: Wang, Yi, et al.
Publicado: (2018)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

HDAC7 inhibits cell proliferation via NudCD1/GGH axis in triple-negative breast cancer
por: Zhu, Mengdi, et al.
Publicado: (2022)

Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
por: Zhang, Shuang, et al.
Publicado: (2022)

The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer
por: Ulhaka, Karan, et al.
Publicado: (2021)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
por: Yoon, Somy, et al.
Publicado: (2016)

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
por: Murahari, Sridhar, et al.
Publicado: (2017)

Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?
por: Eyre, Toby A.
Publicado: (2018)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma
por: Lin, Tzu-Wei, et al.
Publicado: (2017)

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Zhou, Bingyi, et al.
Publicado: (2021)

PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer
por: Al-Khadairi, Ghaneya, et al.
Publicado: (2019)

CD155 contributes to the mesenchymal phenotype of triple‐negative breast cancer
por: Zheng, Qianqian, et al.
Publicado: (2020)

TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer
por: King, Jamie L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_di7u7bthmec5ltug53bc89rp0o